Evaluation of Post-Vaccination Immunity in Children and Adolescents after Viral Hepatitis B Vaccine-Reference-Cited by-同舟云学术

Evaluation of Post-Vaccination Immunity in Children and Adolescents after Viral Hepatitis B Vaccine

Published:2024-02-24 Issue:1 Volume:21 Page:24-31
ISSN:2500-3089
Container-title:Pediatric pharmacology
language:
Short-container-title:Pediatr. farmakol.

Author:

Khamidulina Anna A.¹^ORCID,Solovеva Irina L.¹^ORCID,Kostinov Mikhail P.²^ORCID,Polishchuk Valentina B.³^ORCID,Firsova Natalia V.⁴^ORCID,Achilov Atabeg B.⁴^ORCID,Nikitina Tatiana N.⁵^ORCID,Isayeva Darya A.¹^ORCID,Petrunina Darya D.¹^ORCID,Korotkova Ksenia M.¹^ORCID,Gerlinger Yekaterina А.¹^ORCID,Magomedova Naida A.⁶^ORCID

Affiliation:

1. Ulyanovsk State University, Institute of Medicine, Ecology and Physical Culture

2. I.I. Mechnikov Research Institute of Vaccines and Sera; I.M. Sechenov First Moscow State Medical University (Sechenov University)

3. I.I. Mechnikov Research Institute of Vaccines and Sera

4. Research Center for Fundamental and Applied Problems of Bioeclology and Biotechnology of Federal State Budgetary Educational Institution of Ulyanovsk State University of Education

5. Department of the Center for Examination and Control of Medical Immunobiological Preparations, Scientific Centre for Expert Evaluation of Medicinal Products

6. I.M. Sechenov First Moscow State Medical University (Sechenov University)

Abstract

Vaccination against viral hepatitis B is an effective method of protection against this infection. There is multiple decrease in the hepatitis B incidence. However, there was increase in chronic hepatitis B by 42.5%, 15 cases of acute viral hepatitis B in children and 2 deaths from this infection were registered according to the state report “On the sanitary and epidemiological wellbeing of the population of the Russian Federation for 2022”. The criteria for evaluating protection against viral hepatitis B are the anti-HBs level and the duration of post-vaccination immunity.Objective. The aim of the study is to evaluate the duration of postvaccination immunity in temporal aspect in children and adolescents vaccinated against viral hepatitis B.Methods. Prospective open-label study was conducted to assess post-vaccination immunity against viral hepatitis B in 143 children and adolescents. The study of anti-HBs was implemented via the immunoenzyme test system “Vectohep B-HBs-antigen”. Microsoft Office Excel 2010 package and the Prism9 program (GraphPad, USA) were used for statistical analysis.Results. It has been shown that hepatitis B vaccine provides 100% seroconversion. However, decrease in anti-HBs levels was revealed already 6 months after vaccination in 15.07% of cases of seronegative individuals, after 1 year their number has increased up to 28.77% of cases. On average, every fourth person had low protective level of anti-HBs. Almost two-thirds of adolescents became seronegative by the age of 14.Conclusion. Vaccination against viral hepatitis B ensures the maximum production of anti-HBs 1 month after the completed vaccination in 100% of cases. Antibody level begins to decrease 6 months after the third completed vaccination against hepatitis B, and in 14 years, 72.74% of those immunized become seronegative. All of these dictates the need to consider a booster dose in adolescents at the age of 14 years.

Publisher

Paediatrician Publishers LLC

Reference20 articles.

1. O sostoyanii sanitarno-epidemiologicheskogo blagopoluchiya naseleniya v Rossiiskoi Federatsii v 2022 godu: State report». (In Russ).] Доступно по: https://www.rospotrebnadzor.ru/documents/details.php?ELEMENT_ID=25076. Ссылка активна на 08.02.2024.

2. Namazova-Baranova LS, Fedoseenko MV, Shakhtatinskaya FCh, et al. Assessment of documented vaccination of adolescent schoolchildren in various cities of Russian Federation. Pediatricheskaya farmakologiya — Pediatric pharmacology. 2022;19(6):514–524. (In Russ). https://doi.org/10.15690/pf.v19i6.2493

3. Plan po realizatsii Strategii razvitiya immunoprofilaktiki infektsionnykh boleznei na period do 2035 goda (approved by the Decree of the Government of the Russian Federation of March 29 2021 No. 774-р) (In Russ). Доступно по: http://static.government.ru/media/files/1AqqD3UXGsApOYZ8F5KxaUwnlNTyVRNB.pdf. Ссылка активна на 08.02.2024.

4. Argaw B, Mihret A, Aseffa A, et al. Sero-prevalence of hepatitis B virus markers and associated factors among children in Hawassa City, southern Ethiopia. BMC Infect Dis. 2020;20(1):528. https://doi.org/10.1186/s12879-020-05229-7

5. Mastrodomenico M, Muselli M, Provvidenti L, et al. Longterm immune protection against HBV: associated factors and determinants. Hum Vaccin Immunother. 2021;17(7):2268–2272. https://doi.org/10.1080/21645515.2020.1852869